Health Care & Life Sciences » Biotechnology | Kura Oncology Inc.

Kura Oncology Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2014
2015
2016
2017
2018
Cost of Goods Sold (COGS) incl. D&A
1.50
20.00
31.00
30.00
10
Gross Income
1.50
20.00
31.00
30.00
10
SG&A Expense
3,932.70
23,577.00
28,336.00
36,047.00
62,873
EBIT
3,934.20
23,597.00
28,367.00
36,077.00
62,883
Unusual Expense
-
268.00
-
-
498
Non Operating Income/Expense
300.00
1,200.00
885.00
780.00
735
Interest Expense
37.10
88.00
577.00
888.00
970
Pretax Income
3,671.30
22,625.00
27,560.00
35,434.00
60,447
Consolidated Net Income
3,671.30
22,625.00
27,560.00
35,434.00
60,447
Net Income
3,671.30
22,625.00
27,560.00
35,434.00
60,447
Net Income After Extraordinaries
3,671.30
22,625.00
27,560.00
35,434.00
60,447
Net Income Available to Common
3,671.30
22,625.00
27,560.00
35,434.00
60,447
EPS (Basic)
12.99
2.28
1.47
1.52
1.72
Basic Shares Outstanding
18,820.70
9,933.00
18,701.00
23,237.00
35,191
EPS (Diluted)
0.20
2.28
1.47
1.52
1.72
Diluted Shares Outstanding
18,820.70
9,933.00
18,701.00
23,237.00
35,191
EBITDA
3,932.70
23,577.00
28,336.00
36,047.00
62,873
Non-Operating Interest Income
-
128.00
499.00
751.00
3,169

About Kura Oncology

View Profile
Address
3033 Science Park Road
San Diego California 92121
United States
Employees -
Website http://www.kuraoncology.com
Updated 07/08/2019
Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia; KO-947 which is an ERK inhibitor for MAPK Pathway Tumors; and KO-539 which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E.